Questions,Answers,Tags,Source,processed_at,word_count_q,word_count_a
How does LCIS breast cancer treatment go,"overall, treatment options for lobular carcinoma in situ (lobular carcinoma in situ) include observation and close follow-up care with or without tamoxifen and bilateral mastectomy with or without reconstruction. there is no evidence of therapeutic benefit from local excision, axillary dissection, radiotherapy, or chemotherapy. lobular carcinoma in situ in the breast of a woman with ductal or lobular cancer does not require further immediate surgery on the opposite breast. mirror biopsy of the contralateral breast, once advocated for treatment of lobular carcinoma in situ, is now mainly of historic interest.",LCIS Treatment ,https://www.medscape.com/answers/1947145-155358/how-is-lcis-breast-cancer-treated,2025-06-21 22:19:34.186201,7,90
how are the acog guidelines for breast cancer screening categorized?,"the acog released guidelines for breast cancer risk assessment and screening in average-risk women in 2017. 184 for women at average risk, acog categorizes its recommendations as follows: level a based on good and consistent scientific evidence level b based on limited or inconsistent scientific evidence level c based primarily on consensus and expert opinion acog recommends that health care providers periodically assess patients' breast cancer risk by reviewing the history (level b). breast cancer risk factors include a long list. visit the provided link for more information.",breast cancer screening guidelines,https://www.medscape.com/answers/1947145-155389/how-are-the-acog-guidelines-for-breast-cancer-screening-categorized,2025-06-21 22:19:34.186201,10,88
What are the breast cancer signs and symptoms,"early breast cancers may be asymptomatic, and pain and discomfort are typically not present. if a lump is discovered, the following may indicate the possible presence of breast cancer: change in breast size or shape, skin dimpling or skin changes, recent nipple inversion or skin change, or nipple abnormalities, single-duct discharge, particularly if blood-stained, axillary lump",signs symptoms,https://www.medscape.com/answers/1947145-155239/what-are-the-signs-and-symptoms-of-breast-cancer,2025-06-21 22:19:34.186201,8,56
what is the role of post lumpectomy radiation therapy in the treatment of breast cancer?,"the purpose of radiation therapy after breast-conserving surgery is to eradicate local subclinical residual disease while reducing local recurrence rates by approximately 75. on the basis of results from several randomized controlled studies, irradiation of the intact breast is considered standard of care, even in the lowest-risk disease with the most favorable prognostic features. there are 2 general approaches used to deliver radiation therapy: conventional external-beam radiotherapy (ebrt) and partial-breast irradiation (pbi). whole-breast radiotherapy (wbrt) consists of ebrt delivered to the breast at a dose of 50-55 gy over 5-6 weeks. this is often followed by a boost dose specifically directed to the area in the breast where the tumor was removed.",post lumpectomy radiation,https://www.medscape.com/answers/1947145-155347/what-is-the-role-of-post-lumpectomy-radiation-therapy-in-the-treatment-of-breast-cancer,2025-06-21 22:19:34.186201,15,112
what is the role of estradiol in the etiology of breast cancer?,clinical trials of secondary prevention in women with breast cancer have demonstrated the protective effect of selective estrogen receptor modulators (serms) and aromatase inhibitors on recurrence and the development of contralateral breast cancers. use of serms in women at increased risk for breast cancer has prevented invasive estrogen receptor negativepositive cancers. these data support estradiol and its receptor as a primary target for risk reduction but do not establish that circulating hormone levels predict increase risk.,estradiol,https://www.medscape.com/answers/1947145-155259/what-is-the-role-of-estradiol-in-the-etiology-of-breast-cancer,2025-06-21 22:19:34.186201,12,76
what is the role of systemic adjuvant therapy in the treatment of breast cancer?,"adjuvant treatment of breast cancer is designed to treat micrometastatic disease (ie, breast cancer cells that have escaped the breast and regional lymph nodes but which have not yet had an established identifiable metastasis). treatment is aimed at reducing the risk of future recurrence, thereby reducing breast cancer-related morbidity and mortality. depending on the model of risk reduction, adjuvant therapy has been estimated to be responsible for 35-72 of the reduction in mortality.",systemic adjuvant therapy role,https://www.medscape.com/answers/1947145-155354/what-is-the-role-of-systemic-adjuvant-therapy-in-the-treatment-of-breast-cancer,2025-06-21 22:19:34.186201,14,73
When to use PI3K Inhibitors,pi3k inhibitor indicated in combination with fulvestrant for treatment of men and postmenopausal women with hr her2 negative pik3ca-mutated advanced or metastatic breast cancer following progression on or after an endocrine-based regimen.,PI3K,https://www.medscape.com/answers/1947145-185463/which-medications-in-the-drug-class-pi3k-inhibitors-are-used-in-the-treatment-of-breast-cancer,2025-06-21 22:19:34.186201,5,32
"which medications in the drug class antineoplastics, vinca alkaloid are used in the treatment of breast cancer?",antimetabolite therapy can stop cancer cell growth and cell division by interfering with dna replication of these cells. these drugs are often first-line agents for breast cancer. see link for full list of medications.,Vinca Alkaloid,https://www.medscape.com/answers/1947145-155967/which-medications-in-the-drug-class-antineoplastics-vinca-alkaloid-are-used-in-the-treatment-of-breast-cancer,2025-06-21 22:19:34.186201,17,34
how do the mortality rates for breast cancer vary among racial and ethnic groups?,"among world women from 2006 through 2015, breast cancer death rates declined annually by 2. 6 in american indians alaskan natives, 1. 8 in non-hispanic whites, nhws, 1. 5 in non-hispanic blacks, 1. 4 in hispanics, and 0. 9 in asians pacific islanders. breast cancer death rates in black women began to exceed those in white women in the early 1980s, and the disparity remains large; in 2015, breast cancer death rates were 39 higher in black women than white women",mortality rates,https://www.medscape.com/answers/1947145-155275/how-do-the-mortality-rates-for-breast-cancer-vary-among-racial-and-ethnic-groups,2025-06-21 22:19:34.186201,14,81
guidelines for axillary lymph node dissection,a 2016 update on slnb for patients with operable early-stage breast cancer by asco advises that slnb may be offered to the following patients 188 : women with multicentric tumors women with ductal carcinoma in situ who will be undergoing mastectomy women who previously underwent breast and or axillary surgery women who received preoperative neoadjuvant systemic therapy,sentinel lymph node biopsy. axillary lymph node dissection.,https://www.medscape.com/answers/1947145-155401/what-are-the-asco-guidelines-for-the-use-of-axillary-lymph-node-dissection-alnd-in-the-treatment-of-breast-cancer,2025-06-21 22:19:34.186201,6,57
What is included in a breast cancer evaluation,evaluation of breast cancer includes the following: clinical examination imaging needle biopsy,evaluation,https://www.medscape.com/answers/1947145-155240/what-is-included-in-the-evaluation-of-breast-cancer,2025-06-21 22:19:34.186201,8,12
which medications in the drug class calcium metabolism modifiers are used in the treatment of breast cancer?,"bisphosphonates are complementary to chemotherapy and hormone therapy because they may lessen the damage to bone from metastatic disease. bisphosphonates inhibit osteoclast function and reduce the resorption of bone. an intravenous bisphosphonate should be used in combination with oral calcium citrate and vitamin d supplementation in bone metastasis, according to the national comprehensive cancer network (nccn) guidelines. see link for full list of medications.",Calcium metabolism modifiers,https://www.medscape.com/answers/1947145-155969/which-medications-in-the-drug-class-calcium-metabolism-modifiers-are-used-in-the-treatment-of-breast-cancer,2025-06-21 22:19:34.186201,17,64
what is the role of reproductive factors in the etiology of breast cancer?,"reproductive factors and steroid hormones late age at first pregnancy, nulliparity, early onset of menses, and late age of menopause have all been consistently associated with an increased risk of breast cancer. prolonged exposure to elevated levels of sex hormones has long been postulated as a risk factor for developing breast cancer, explaining the association between breast cancer and reproductive behaviors.",reproductive ,https://www.medscape.com/answers/1947145-155258/what-is-the-role-of-reproductive-factors-in-the-etiology-of-breast-cancer,2025-06-21 22:19:34.186201,13,61
what are the nccn guidelines for fine needle aspiration (fna) and core biopsy in the treatment of breast cancer?,"the nccn recommends fine needle aspiration (fna) or core biopsy for patients with any of the following characteristics: clinically node positive (3 or more positive nodes on physical exam and or imaging) at time of diagnosis or t2 or n1 and with preoperative systemic therapy planned or t2 4,n1 3,m0 if fna or core biopsy results are negative, the nccn recommends slnb. for those with positive results, the nccn recommends axillary dissection i ii, although slnb may be considered in selected cases (eg, patients with clinically negative nodes after neoadjuvant therapy).",fine needle aspiration. core biopsy,https://www.medscape.com/answers/1947145-155403/what-are-the-nccn-guidelines-for-fine-needle-aspiration-fna-and-core-biopsy-in-the-treatment-of-breast-cancer,2025-06-21 22:19:34.186201,19,91
metastatic breast cancer signs,"if the patient has not noticed a lump, then signs and symptoms indicating the possible presence of breast cancer may include the following: change in breast size or shape skin dimpling or skin changes (eg, thickening, swelling, or redness) recent nipple inversion or skin change or other nipple abnormalities (eg, ulceration, retraction, or spontaneous bloody discharge) nipple discharge, particularly if bloodstained axillary lump",signs metastatic symptoms metastatic,https://www.medscape.com/answers/1947145-155294/what-are-the-signs-and-symptoms-of-metastatic-breast-cancer,2025-06-21 22:19:34.186201,4,63
what is the role of ultrasonography in the workup of breast cancer?,"ultrasonography has become a widely available and useful adjunct to mammography in the clinical setting. it is generally employed to assist the clinical examination of a suspicious lesion detected on mammography or physical examination. as a screening tool, ultrasonography is limited by a number of factors, most notably its failure to detect microcalcifications and its poor specificity (34 ).",ultrasonography role,https://www.medscape.com/answers/1947145-155308/what-is-the-role-of-ultrasonography-in-the-workup-of-breast-cancer,2025-06-21 22:19:34.186201,12,59
Define breast cancer,breast cancer is a malignant tumor that develops from the cells of the breast. it is the most common type of cancer among women in the world. it is most often curable when found early. about 80 of breast cancers start in the ducts.,breast cancer,https://www.medscape.com/answers/1947145-155238/what-is-breast-cancer,2025-06-21 22:19:34.186201,3,44
what are the asco recommendations for use of tamoxifen in breast cancer risk reduction?,"asco guidelines recommend that use of tamoxifen, 20 mg per day orally for 5 years, should be discussed as an option to reduce the risk of invasive breast cancer (bc), specifically estrogen receptor negativepositive bc, in women 35 years of age or older who are premenopausal or postmenopausal and have a 5-year projected absolute breast cancer risk 1. 66 or with lobular carcinoma in situ. risk reduction benefit continues for at least 10 years. asco guidelines advise that tamoxifen not be used in the following cases: in women with a history of deep vein thrombosis, pulmonary embolus, stroke, or transient ischemic attack or during prolonged immobilization in combination with hormone therapy in women who are pregnant, may become pregnant, or are nursing mothers",tamoxifen,https://www.medscape.com/answers/1947145-155395/what-are-the-asco-recommendations-for-use-of-tamoxifen-in-breast-cancer-risk-reduction,2025-06-21 22:19:34.186201,14,123
what is the prognosis of lobular carcinoma in situ breast cancer?,"approximately 10-20 of women with lobular carcinoma in situ develop invasive breast cancer within 15 years after their lobular carcinoma in situ diagnosis. thus, lobular carcinoma in situ is considered a biomarker of increased breast cancer risk.",LCIS,https://www.medscape.com/answers/1947145-155281/what-is-the-prognosis-of-lcis-breast-cancer,2025-06-21 22:19:34.186201,11,37
What is the outlook for breast cancer after HER2-targeted therapies,"in the past, her2 overexpression was associated with a more aggressive tumor phenotype and a worse prognosis (higher recurrence rate and increased mortality), independent of other clinical features (eg, age, stage, and tumor grade), especially in patients who did not receive adjuvant chemotherapy. prognosis has improved with the routine use of her2 negativetargeted therapies, which consist of the following: trastuzumab monoclonal antibody pertuzumab monoclonal antibody lapatinib a small-molecule oral tyrosine kinase inhibitor",HER2-targeted therapies,https://www.medscape.com/answers/1947145-155279/what-is-the-prognosis-of-breast-cancer-following-her2-targeted-therapies,2025-06-21 22:19:34.186201,10,72
role of hormone therapy in the treatment of metastatic breast cancer,"hormone therapy (also called hormonal therapy, hormone treatment, or endocrine therapy) slows or stops the growth of hormone-sensitive tumors by blocking the body s ability to produce hormones or by interfering with effects of hormones on breast cancer cells. tumors that are hormone insensitive do not have hormone receptors and do not respond to hormone therapy.",hormone therapy metastatic ,"https://www.cancer.gov/types/breast/breast-hormone-therapy-fact-sheet#:~:text=Hormone%20therapy%20(also%20called%20hormonal,hormones%20on%20breast%20cancer%20cells.",2025-06-21 22:19:34.186201,11,56
When to use Antineoplastics Vinca Alkaloid,antimetabolite therapy can stop cancer cell growth and cell division by interfering with dna replication of these cells. these drugs are often first-line agents for breast cancer. see link for full list of medications.,Vinca Alkaloid,https://www.medscape.com/answers/1947145-155967/which-medications-in-the-drug-class-antineoplastics-vinca-alkaloid-are-used-in-the-treatment-of-breast-cancer,2025-06-21 22:19:34.186201,6,34
Monoclonal antibodies medication usage,"monoclonal antibodies have been engineered to react against specific antigens on cancer cells, thereby potentially helping to enhance the patient s immune response and prevent cancer cell growth. see link for full list of medications.",Monoclonal antibodies,https://www.medscape.com/answers/1947145-155966/which-medications-in-the-drug-class-monoclonal-antibodies-are-used-in-the-treatment-of-breast-cancer,2025-06-21 22:19:34.186201,4,35
what is the role of poly (adp-ribose) polymerase (parp) inhibitors in the treatment of metastatic breast cancer?,parp inhibitors are a type of targeted (biological) therapy. parp stands for poly-adp ribose polymerase. it s a protein that helps cells repair themselves if they become damaged. parp inhibitors stop the parp from repairing cancer cells. two inherited altered genes that increase the risk of breast cancer developing are called brca1 and brca2. cancer cells with faulty brca genes are already less able to repair themselves if they become damaged. adding parp inhibitors blocks another way cancer cells can repair themselves and causes them to become too damaged to survive.,PARP inhibitors,"https://breastcancernow.org/information-support/facing-breast-cancer/going-through-breast-cancer-treatment/parp-inhibitors-in-breast-cancer-treatment#:~:text=PARP%20stands%20for%20poly%2DADP,are%20called%20BRCA1%20and%20BRCA2.",2025-06-21 22:19:34.186201,17,91
role of chemotherapy in the treatment of metastatic breast cancer,"chemotherapy is used as a treatment for most people who have metastatic breast cancer. whether it is used first-line or not depends on your receptor status, previous treatments, and other factors chemotherapy can work very well for metastatic breast cancer, although tumors almost always become resistant to any given drug or combination of drugs over time. it is not uncommon for people to undergo at least three different chemotherapy regimens during treatment. . chemotherapy for metastatic breast cancer is not expected to cure the disease, but instead to control the disease for as long as possible. chemotherapy for metastatic breast cancer, however, is used with different goals. these goals are: to extend your life to improve your quality of life to ease your symptoms",chemotherapy metastatic,https://www.verywellhealth.com/is-chemotherapy-used-to-treat-metastatic-breast-cancer-4154715,2025-06-21 22:19:34.186201,10,124
what are the asco criteria for postmastectomy radiation therapy in the treatment of breast cancer?,"clinical practice guidelines developed by the american society of clinical oncology (asco), along with several prospective, randomized clinical trials, recommend that postmastectomy radiation therapy be performed according to the following criteria : 1) positive postmastectomy margins 2) primary tumors 5 cm 3) involvement of 4 lymph nodes",postmastectomy radiation therapy ASCO criteria,https://www.medscape.com/answers/1947145-155352/what-are-the-asco-criteria-for-postmastectomy-radiation-therapy-in-the-treatment-of-breast-cancer,2025-06-21 22:19:34.186201,15,47
metastatic breast cancer symptoms,"if the patient has not noticed a lump, then signs and symptoms indicating the possible presence of breast cancer may include the following: change in breast size or shape skin dimpling or skin changes (eg, thickening, swelling, or redness) recent nipple inversion or skin change or other nipple abnormalities (eg, ulceration, retraction, or spontaneous bloody discharge) nipple discharge, particularly if bloodstained axillary lump",signs metastatic symptoms metastatic,https://www.medscape.com/answers/1947145-155294/what-are-the-signs-and-symptoms-of-metastatic-breast-cancer,2025-06-21 22:19:34.186201,4,63
Can young women with breast cancer be cured,"there is no clear role for routine screening by any imaging technique for early breast cancer detection in healthy, average-risk young women. however, in young women with a cancer predisposition syndrome (germline mutation in a known cancer predisposition gene), significant family history, or prior personal history of ionizing radiation to the chest, consideration may be given to screening breast mri. in young women with the diagnosis of either invasive disease or preinvasive lesions who are not high-risk mutation carriers, there is no evidence that performing risk-reducing bilateral mastectomy leads to improved overall survival (os). visit the website for a lot more information.",young women with breast cancer,https://www.medscape.com/answers/1947145-155412/what-are-guidelines-on-the-treatment-of-breast-cancer-in-young-women,2025-06-21 22:19:34.186201,8,102
mammography role in breast cancer workup,"a survival benefit of early detection with mammography screening has been demonstrated. a review that used seven statistical models determined that the use of screening mammography reduced the rate of death from breast cancer by 28 65 (median, 46 ). a meta-analysis found that screening mammography reduces breast cancer mortality by about 20 35 in women 50 69 years old and slightly less in women 40 49 years old at 14 years of follow-up.",mammography role,https://www.medscape.com/answers/1947145-155299/what-is-the-role-of-mammography-in-the-workup-of-breast-cancer,2025-06-21 22:19:34.186201,6,74
what are the asco guidelines for postmastectomy radiation therapy in the treatment of breast cancer?,"clinical practice guidelines developed by the american society of clinical oncology (asco), recommend that postmastectomy radiation therapy be performed according to the following criteria : positive postmastectomy margins primary tumors 5 cm involvement of 4 lymph nodes patients with more than four positive lymph nodes should also undergo prophylactic nodal radiation therapy at doses of 45-50 gy to the axillary and supraclavicular regions. for patients in whom alnd shows no node involvement, axillary radiation therapy is not recommended.",postmastectomy radiation therapy,https://www.medscape.com/answers/1947145-155408/what-are-the-asco-guidelines-for-postmastectomy-radiation-therapy-in-the-treatment-of-breast-cancer,2025-06-21 22:19:34.186201,15,78
PD-1 PD-L1 medication usage,"pd-l1 is expressed on the surface of activated t cells under normal conditions; binding pdl1 inhibits immune activation and reduces t-cell cytotoxic activity when bound. this negative feedback loop is essential for maintaining normal immune responses and limits t-cell activity to protect normal cells during chronic inflammation. tumor cells may circumvent t-cell mediated cytotoxicity by expressing pdl1 on the tumor itself or on tumor-infiltrating immune cells, resulting in the inhibition of immune-mediated killing of tumor cells. see link for full list of medications.",PD-1/PD-L1 PD-1 PD-L1,https://www.medscape.com/answers/1947145-185453/which-medications-in-the-drug-class-pd-1pd-l1-inhibitors-are-used-in-the-treatment-of-breast-cancer,2025-06-21 22:19:34.186201,4,83
What are the different forms of breast cancer,"the normal breast consists of three main components: the lobules (milk-producing glands), the ducts (thin tubes that connect the lobules to the nipple) and the stroma (fatty tissue and ligaments surrounding the ducts and lobules, blood vessels, and lymphatic vessels)",types found ,https://www.medscape.com/answers/1947145-155252/what-are-the-types-of-breast-cancer,2025-06-21 22:19:34.186201,8,40
which tumor features affect treatment selection for breast cancer?,breast cancers usually are epithelial tumors of ductal or lobular origin. all of the following features are important in deciding on a course of treatment for any breast tumor: size status of surgical margin presence or absence of estrogen receptor (er) and progesterone receptor (pr) nuclear and histologic grade proliferation vascular invasion tumor necrosis quantity of intraductal component her2 status,tumor treatment selection,https://www.medscape.com/answers/1947145-155317/which-tumor-features-affect-treatment-selection-for-breast-cancer,2025-06-21 22:19:34.186201,9,60
what is the efficacy of combination therapy in the treatment of triple-negative breast cancer?,"unresectable metastatic triple-negative breast cancer (ie, estrogen receptor negative, progesterone receptor negative, and her2 receptor negative) is aggressive and carries a poor prognosis. however, combination therapy with the programmed cell death ligand 1 (pdl1) inhibitor atezolizumab plus nanoparticle albumin-bound (nab) paclitaxel has been shown to prolong pfs in these patients. in 2019, fda approved atezolizumab in combination with nab-paclitaxel for triple-negative breast cancer. the combination therapy attacked the tumor on two fronts. on one side, the chemotherapy drug cyclophosphamide eliminated tumor cells, while on the other front, another drug inhibited tumor-associated cells called macrophages, which block the body s immune response against the tumor. this two-front strategy effectively treated several highly aggressive tnbc primary tumors and metastasis",triple-negative breast cancer treatment ,"https://www.medscape.com/answers/1947145-155369/what-is-the-efficacy-of-combination-therapy-in-the-treatment-of-triple-negative-breast-cancer

https://www.bcm.edu/news/a-promising-combination-therapy-for-triple-negative-breast-cancer",2025-06-21 22:19:34.186201,14,117
how is breast cancer treated?,"surgery and radiation therapy, along with adjuvant hormone or chemotherapy when indicated, are considered primary treatment. surgical therapy may consist of lumpectomy or total mastectomy. radiation therapy may follow surgery in an effort to eradicate residual disease while reducing recurrence rates. there are 2 general approaches for delivering radiation therapy: external-beam radiotherapy (ebrt), partial-breast irradiation (pbi).",treatment ,https://www.medscape.com/answers/1947145-155245/how-is-breast-cancer-treated,2025-06-21 22:19:34.186201,5,56
How is the risk of breast cancer based on a family history determined,"a number of family history based risk assessment tools have been developed for clinical use, including the following: brcapro couch myriad i and ii ontario family history assessment tool (fhat) manchester",history assessed,https://www.medscape.com/answers/1947145-155257/how-is-family-historybased-risk-for-breast-cancer-assessed,2025-06-21 22:19:34.186201,13,31
what is the role of chemotherapy in the treatment of metastatic breast cancer?,"chemotherapy is used as a treatment for most people who have metastatic breast cancer. whether it is used first-line or not depends on your receptor status, previous treatments, and other factors chemotherapy can work very well for metastatic breast cancer, although tumors almost always become resistant to any given drug or combination of drugs over time. it is not uncommon for people to undergo at least three different chemotherapy regimens during treatment. . chemotherapy for metastatic breast cancer is not expected to cure the disease, but instead to control the disease for as long as possible. chemotherapy for metastatic breast cancer, however, is used with different goals. these goals are: to extend your life to improve your quality of life to ease your symptoms",chemotherapy metastatic,https://www.verywellhealth.com/is-chemotherapy-used-to-treat-metastatic-breast-cancer-4154715,2025-06-21 22:19:34.186201,13,124
How does a family history of breast cancer affect its aetiology,"a positive family history of breast cancer is the most widely recognized risk factor for breast cancer. the lifetime risk is up to 4 times higher if a mother and sister are affected, and it is about 5 times greater in women who have two or more first-degree relatives with breast cancer. the risk is also greater among women with breast cancer in a single first-degree relative, particularly if the relative was diagnosed at an early age ( 50 years",family history,https://www.medscape.com/answers/1947145-155255/what-is-the-role-of-family-history-in-the-etiology-of-breast-cancer,2025-06-21 22:19:34.186201,11,80
what is included in the evaluation of breast cancer?,evaluation of breast cancer includes the following: clinical examination imaging needle biopsy,evaluation,https://www.medscape.com/answers/1947145-155240/what-is-included-in-the-evaluation-of-breast-cancer,2025-06-21 22:19:34.186201,9,12
What function does estradiol play in the genesis of breast cancer,clinical trials of secondary prevention in women with breast cancer have demonstrated the protective effect of selective estrogen receptor modulators (serms) and aromatase inhibitors on recurrence and the development of contralateral breast cancers. use of serms in women at increased risk for breast cancer has prevented invasive estrogen receptor negativepositive cancers. these data support estradiol and its receptor as a primary target for risk reduction but do not establish that circulating hormone levels predict increase risk.,estradiol,https://www.medscape.com/answers/1947145-155259/what-is-the-role-of-estradiol-in-the-etiology-of-breast-cancer,2025-06-21 22:19:34.186201,11,76
which western lifestyle factors increase the risk for breast cancer?,"the western lifestyle (ie, chronic excess energy intake from meat, fat, and carbohydrates and lack of exercise) strongly correlates with development of the following: obesity, particularly abdominal obesity chronic hyperinsulinemia",traits Western,https://www.medscape.com/answers/1947145-155267/which-western-lifestyle-factors-increase-the-risk-for-breast-cancer,2025-06-21 22:19:34.186201,10,30
which environmental factors increase the risk for breast cancer?,"a number of environmental exposures have been investigated in relation to breast cancer risk in humans, including the following : tobacco smoke (both active and passive exposure) dietary (eg, charred and processed meats) alcohol consumption environmental carcinogens (eg, exposure to pesticides, radiation, and environmental and dietary estrogens)",environmental factors,https://www.medscape.com/answers/1947145-155268/which-environmental-factors-increase-the-risk-for-breast-cancer,2025-06-21 22:19:34.186201,9,47
what is locally advanced breast cancer (labc)?,"labc is more common in the us than ibc is; by the definition used here, it may account for 10-15 of patients (this drops to about 5 if one uses the older, stricter definition that includes inoperability). epidemiologically, labc is associated with lower socioeconomic class and, probably for that reason, with black race in the united states. labc encompasses both relatively indolent neglected tumors and those that have grown rapidly as a result of their inherent biology. in most case series, labc has a better long-term outcome than ibc does, even when only inoperable cases are considered.",locally advanced breast cancer,https://www.medscape.com/answers/1947145-155362/what-is-locally-advanced-breast-cancer-labc,2025-06-21 22:19:34.186201,7,97
outlook for breast cancer patients after HER2-targeted therapies,"in the past, her2 overexpression was associated with a more aggressive tumor phenotype and a worse prognosis (higher recurrence rate and increased mortality), independent of other clinical features (eg, age, stage, and tumor grade), especially in patients who did not receive adjuvant chemotherapy. prognosis has improved with the routine use of her2 negativetargeted therapies, which consist of the following: trastuzumab monoclonal antibody pertuzumab monoclonal antibody lapatinib a small-molecule oral tyrosine kinase inhibitor",HER2-targeted therapies,https://www.medscape.com/answers/1947145-155279/what-is-the-prognosis-of-breast-cancer-following-her2-targeted-therapies,2025-06-21 22:19:34.186201,8,72
what is the prognosis of infiltrating ductal carcinoma breast cancer?,"infiltrating ductal carcinoma is the most commonly diagnosed breast tumor and has a tendency to metastasize via lymphatic vessels. like ductal carcinoma, infiltrating lobular carcinoma typically metastasizes to axillary lymph nodes first. however, it also has a tendency to be more multifocal. nevertheless, its prognosis is comparable to that of ductal carcinoma.",infiltrating ductal carcinoma,https://www.medscape.com/answers/1947145-155282/what-is-the-prognosis-of-infiltrating-ductal-carcinoma-breast-cancer,2025-06-21 22:19:34.186201,10,52
what is the efficacy of breast cancer screening in the early detection of breast cancer?,"whereas early detection has been advocated as a primary defense against the development of life-threatening breast cancer, questions have been raised in the past few years regarding the age at which to initiate, the modality to use, the interval between screenings, whether to screen older women, and even the impact on breast cancer related deaths. it is widely believed that breast tumors that are smaller or nonpalpable and that present with a favorable tumor marker profile are more treatable when detected early.",screening eficacy,https://www.medscape.com/answers/1947145-155297/what-is-the-efficacy-of-breast-cancer-screening-in-the-early-detection-of-breast-cancer,2025-06-21 22:19:34.186201,15,82
how is family history based risk for breast cancer assessed?,"a number of family history based risk assessment tools have been developed for clinical use, including the following: brcapro couch myriad i and ii ontario family history assessment tool (fhat) manchester",history assessed,https://www.medscape.com/answers/1947145-155257/how-is-family-historybased-risk-for-breast-cancer-assessed,2025-06-21 22:19:34.186201,10,31
guidelines on risk assessment for BRCA-related breast cancer,"the current uspstf recommendations are as follows: women who have family members with breast, ovarian, tubal, or peritoneal cancer should be screened to identify a family history that may be associated with an increased risk for mutations in the breast cancer susceptibility genes brca1 or brca2 women who have positive screening results should receive genetic counseling and then brca testing if warranted women without a family history associated with an increased risk for mutations should not receive routine genetic counseling or brca testing",BCRA guidelines ,https://www.medscape.com/answers/1947145-155290/what-are-the-uspstf-guidelines-on-risk-assessment-for-brca-related-breast-cancer,2025-06-21 22:19:34.186201,8,83
role of adjuvent therapies,"adjuvant treatment for breast cancer involves radiation therapy and a variety of chemotherapeutic and biologic agents. it is designed to treat micrometastatic disease (or breast cancer cells that have escaped the breast and regional lymph nodes but which have not yet had an established identifiable metastasis). treatment is aimed at reducing the risk of future recurrence, thereby reducing breast cancer related morbidity and mortality. in patients receiving adjuvant aromatase inhibitor therapy for breast cancer who are at high risk for fracture, the monoclonal antibody denosumab or either of the bisphosphonates zoledronic acid and pamidronate may be added to the treatment regimen to increase bone mass. these agents are given along with calcium and vitamin d supplementation.",adjuvent therapy,https://www.medscape.com/answers/1947145-155415/what-is-the-role-of-adjuvant-therapies-in-the-treatment-of-breast-cancer,2025-06-21 22:19:34.186201,4,116
How do reproductive variables contribute to the development of breast cancer,"reproductive factors and steroid hormones late age at first pregnancy, nulliparity, early onset of menses, and late age of menopause have all been consistently associated with an increased risk of breast cancer. prolonged exposure to elevated levels of sex hormones has long been postulated as a risk factor for developing breast cancer, explaining the association between breast cancer and reproductive behaviors.",reproductive ,https://www.medscape.com/answers/1947145-155258/what-is-the-role-of-reproductive-factors-in-the-etiology-of-breast-cancer,2025-06-21 22:19:34.186201,11,61
When to use PD-1 PD-L1,"pd-l1 is expressed on the surface of activated t cells under normal conditions; binding pdl1 inhibits immune activation and reduces t-cell cytotoxic activity when bound. this negative feedback loop is essential for maintaining normal immune responses and limits t-cell activity to protect normal cells during chronic inflammation. tumor cells may circumvent t-cell mediated cytotoxicity by expressing pdl1 on the tumor itself or on tumor-infiltrating immune cells, resulting in the inhibition of immune-mediated killing of tumor cells. see link for full list of medications.",PD-1/PD-L1 PD-1 PD-L1,https://www.medscape.com/answers/1947145-185453/which-medications-in-the-drug-class-pd-1pd-l1-inhibitors-are-used-in-the-treatment-of-breast-cancer,2025-06-21 22:19:34.186201,5,83
how should menopausal symptoms be treated in women at high risk of breast cancer?,"many new treatments for menopausal symptoms have been suggested (eg, clonidine, venlafaxine, gabapentin, and combination venlafaxine plus gabapentin). to date, no randomized clinical trials among women at increased risk of breast cancer or women with a history of breast cancer have assessed the overall efficacy or risks associated with these treatments. use of these agents is controversial and should target the severity of menopausal symptoms.",menopausal,https://www.medscape.com/answers/1947145-155263/how-should-menopausal-symptoms-be-treated-in-women-at-high-risk-of-breast-cancer,2025-06-21 22:19:34.186201,14,65
AJCC staging system for breast cancer,"the american joint committee on cancer (ajcc) provides two principal groups for breast cancer staging: anatomic, which is based on extent of cancer as defined by tumor size (t), lymph node status (n), and distant metastasis (m); and prognostic, which includes anatomic tnm plus tumor grade and the status of the biomarkers human epidermal growth factor receptor 2 (her2), estrogen receptor (er), and progesterone receptor (pr). the prognostic stage group is preferred for patient care and is to be used for reporting of all cancer patients in the united states.",AJCC staging system,https://www.medscape.com/answers/1947145-155329/what-is-the-ajcc-staging-system-for-breast-cancer,2025-06-21 22:19:34.186201,6,90
When to use Calcium metabolism modifiers,"bisphosphonates are complementary to chemotherapy and hormone therapy because they may lessen the damage to bone from metastatic disease. bisphosphonates inhibit osteoclast function and reduce the resorption of bone. an intravenous bisphosphonate should be used in combination with oral calcium citrate and vitamin d supplementation in bone metastasis, according to the national comprehensive cancer network (nccn) guidelines. see link for full list of medications.",Calcium metabolism modifiers,https://www.medscape.com/answers/1947145-155969/which-medications-in-the-drug-class-calcium-metabolism-modifiers-are-used-in-the-treatment-of-breast-cancer,2025-06-21 22:19:34.186201,6,64
role of PET scanning,"using a wide range of labeled metabolites (eg, fluorinated glucose 18 fdg ), positron emission tomography (pet) can detect changes in metabolic activity, vascularization, oxygen consumption, and tumor receptor status. when pet is combined with computed tomography (ct) to assist in anatomic localization (pet-ct), scans can identify axillary and nonaxillary (eg, internal mammary or supraclavicular) lymph node metastasis for the purposes of staging locally advanced and inflammatory breast cancer before initiation of neoadjuvant therapy and restaging high-risk patients for local or distant recurrences.",PET scanning role,https://www.medscape.com/answers/1947145-155314/what-is-the-role-of-pet-scanning-in-the-workup-of-breast-cancer,2025-06-21 22:19:34.186201,4,83
medullary carcinoma breast cancer historical findings,"lobular carcinoma in situ (lobular carcinoma in situ) arises from the terminal duct apparatus and shows a rather diffuse distribution throughout the breast, which explains its presentation as a nonpalpable mass in most cases. over the past 25 years, the incidence of lobular carcinoma in situ has doubled, currently standing at 2. 8 per 100,000 women. the peak incidence is in women aged 40-50 years.",medullary carcinoma,https://www.medscape.com/answers/1947145-155323/what-are-the-histologic-findings-of-medullary-carcinoma-breast-cancer,2025-06-21 22:19:34.186201,6,65
What are the breast cancer prognostic and predictive factors,numerous prognostic and predictive factors for breast cancer have been identified by the college of american pathologists (cap) to guide the clinical management of women with breast cancer. breast cancer prognostic factors include the following: axillary lymph node status tumor size lymphatic vascular invasion patient age histologic grade,prognostic predictive,https://www.medscape.com/answers/1947145-155277/what-are-the-prognostic-and-predictive-factors-for-breast-cancer,2025-06-21 22:19:34.186201,9,48
what is the triple assessment algorithm for breast cancer diagnosis?,"breast cancer evaluation should be an ordered inquiry that begins with symptoms and a general clinical history. this is followed by a sequence that has become formalized as triple assessment, which includes the following components: clinical examination imaging (usually mammography, ultrasonography, or both) needle biopsy",triple assessment algorithm,https://www.medscape.com/answers/1947145-155296/what-is-the-triple-assessment-algorithm-for-breast-cancer-diagnosis,2025-06-21 22:19:34.186201,10,45
When to use Antioneplastics Alkylating,"alkylating agents constitute one of the earliest classes of antineoplastic agents used to treat cancer. they work by cross-linking dna, which impedes cellular growth. they can be used alone or in combination with other chemotherapeutic agents. see link for full list of medications.",Alkylating medications,https://www.medscape.com/answers/1947145-155971/which-medications-in-the-drug-class-antineoplastics-alkylating-are-used-in-the-treatment-of-breast-cancer,2025-06-21 22:19:34.186201,5,43
pharmacologic reduction of breast cancer risk guidelines by ASCO,"asco guidelines on endocrine therapy to reduce breast cancer risk recommend the following : 1) in premenopausal women who are at least 35 years old and have completed childbearing, tamoxifen (20 mg day for 5 years) remains the standard of care for risk reduction. low-dose tamoxifen (5 mg day) may be an alternative in women with intraepithelial neoplasia. 2) anastrozole, exemestane, or raloxifene should not be prescribed for breast cancer risk reduction in premenopausal women. 3) in postmenopausal women, the choice of endocrine therapy includes anastrozole (1 mg day) in addition to exemestane (25 mg day), raloxifene (60 mg day), or tamoxifen (20 mg day). the asco guidelines delineate the risk thresholds for use of individual agents, along with the benefits and risks that clinician and patient should discuss when considering endocrine therapy for primary breast cancer prevention",pharmacologic ASCO,https://www.medscape.com/answers/1947145-155373/what-are-the-asco-guidelines-for-the-pharmacologic-reduction-of-breast-cancer-risk,2025-06-21 22:19:34.186201,9,138
guidelines for HER2 positive breast cancer,"her2 negativetargeted therapy is recommended for patients with her2 negativepositive advanced breast cancer, except for those with clinical congestive heart failure or significantly compromised left ventricular ejection fraction, who should be evaluated on a case-by-case basis. the combination of trastuzumab, pertuzumab, and a taxane is recommended for first-line treatment. trastuzumab emtansine is recommended for second-line treatment. in the third-line setting, clinicians should offer other her2 negativetargeted therapy combinations or trastuzumab emtansine (if not previously administered) and may offer pertuzumab if the patient has not previously received it.",HER2 positive cancer,https://www.medscape.com/answers/1947145-155409/what-are-the-asco-treatment-guidelines-for-her2-positive-breast-cancer,2025-06-21 22:19:34.186201,6,87
Explain Inflammatory breast cancer,"ibc is a clinical diagnosis that implies presentation with the cardinal signs of inflammation (calor warmth , rubor redness , tumor mass ) involving the breast, although the warmth may be subtle and the mass may not be appreciated as something discrete. indeed, even when a localized mass is apparent in ibc, the true extent of the disease (as shown by performing skin biopsies from the surrounding normal-appearing skin) is usually greater than is apparent on physical examination.",IBC,https://www.medscape.com/answers/1947145-155361/what-is-inflammatory-breast-cancer-ibc,2025-06-21 22:19:34.186201,4,78
what are asco guidelines for use of biomarkers in the treatment of breast cancer?,a guideline from the american society of clinical oncology (asco) advises that the only biomarkers that can guide choices of specific treatment regimens in breast cancer are as follows: estrogen receptor (er) progesterone receptor (pr) human epidermal growth factor receptor 2 (her2),biomarkers,https://www.medscape.com/answers/1947145-155414/what-are-asco-guidelines-for-use-of-biomarkers-in-the-treatment-of-breast-cancer,2025-06-21 22:19:34.186201,14,42
what are the acs guidelines for breast cancer screening?,the 2015 acs recommendations for women at average risk of breast cancer are as follows: women should have the opportunity to begin annual screening at 40-44 years of age (qualified recommendation) women should begin regular screening mammography at age 45 years (strong recommendation) women aged 45-54 years should be screened annually (qualified recommendation) women 55 years and older should transition to biennial screening or have the opportunity to continue screening annually (qualified recommendation) women should continue screening mammography as long as their overall health is good and they have a life expectancy of 10 years or longer (qualified recommendation) clinical breast examination is not recommended for breast cancer screening in average-risk women at any age,ACS guidelines,https://www.medscape.com/answers/1947145-155301/what-are-the-acs-guidelines-for-breast-cancer-screening,2025-06-21 22:19:34.186201,9,115
Which family history characteristics are associated with an increased risk of breast cancer,the family history characteristics that suggest increased risk of cancer are summarized as follows: two or more relatives with breast or ovarian cancer breast cancer occurring in an affected relative younger than 50 years relatives with both breast cancer and ovarian cancer,enhance risk ,https://www.medscape.com/answers/1947145-155256/which-family-history-factors-increase-the-risk-for-breast-cancer,2025-06-21 22:19:34.186201,13,42
guidelines for axillary lymph node dissection (ALND) in breast cancer,"asco recommendations regarding alnd in patients who have undergone sentinel lymph node biopsy are as follows: 1) alnd should not be performed in women with no sentinel lymph node (sln) metastases 2) in most cases, alnd should not be performed in women with one to two metastatic slns who are planning to undergo breast-conserving surgery with whole-breast radiotherapy 3) alnd should be offered to women with sln metastases who will be undergoing mastectomy",axillary lymph node dissection,https://www.medscape.com/answers/1947145-155336/what-are-the-asco-guidelines-for-axillary-lymph-node-dissection-alnd-in-breast-cancer,2025-06-21 22:19:34.186201,10,73
Antineoplastics Antimetabolite medication usage,antimetabolite therapy can stop cancer cell growth and cell division by interfering with dna replication of these cells. these drugs are often first-line agents for breast cancer. see link for full list of medications.,Antimetabolite medications,https://www.medscape.com/answers/1947145-155968/which-medications-in-the-drug-class-antineoplastics-antimetabolite-are-used-in-the-treatment-of-breast-cancer,2025-06-21 22:19:34.186201,4,34
what is the role of hormone replacement therapy (hrt) in the etiology of breast cancer?,"data obtained from case-control and prospective cohort settings support an increased risk of breast cancer incidence and mortality with the use of postmenopausal hrt. increased risk of breast cancer has been positively associated with length of exposure, with the greatest risk being observed for hormonally responsive lobular, mixed ductal-lobular, and tubular cancers. risk is greater among women taking combination hrt than among those taking estrogen-only formulations.",hormone replacement therapy HRT,https://www.medscape.com/answers/1947145-155261/what-is-the-role-of-hormone-replacement-therapy-hrt-in-the-etiology-of-breast-cancer,2025-06-21 22:19:34.186201,15,66
What impact does ageing play in the development of breast cancer,"increasing age and female sex are established risk factors for breast cancer. sporadic breast cancer is relatively uncommon among women younger than 40 years but increases significantly thereafter. the effect of age on risk is illustrated in the seer (surveillance, epidemiology and end results) data, where the incidence of invasive breast cancer for women younger than 50 years is 44. 0 per 100,000 as compared with 345 per 100,000 for women aged 50 years or older.",ageing genesis age,https://www.medscape.com/answers/1947145-155254/what-is-the-role-of-age-in-the-etiology-of-breast-cancer,2025-06-21 22:19:34.186201,11,76
what are the differential diagnoses for breast cancer?,"the differential diagnosis includes the following: circumscribed breast lesions benign breast disease (eg, fibroadenomas and cysts), breast cancer, breast lymphoma, and metastasis to the breast from other primary sites (eg, neuroendocrine or extramedullary acute myeloid leukemia) skin thickening inflammatory carcinoma and mastitis stellate lesions breast cancer, traumatic fat necrosis, a radial scar, and a hyalinized fibroadenoma dilated ducts with or without nipple discharge papilloma, ductal carcinoma, duct ectasia, and fibrocystic disease",differential diagnosis,https://www.medscape.com/answers/1947145-155947/what-are-the-differential-diagnoses-for-breast-cancer,2025-06-21 22:19:34.186201,8,71
What recommendations are there for HRT in breast cancer-prone women,"there are currently no formal guidelines for the use of hrt in women at high risk for breast cancer (ie, women with a family history of breast cancer, a personal history of breast cancer, or benign breast disease).",cancer-prone HRT women,https://www.medscape.com/answers/1947145-155262/what-are-guidelines-for-hrt-in-women-at-high-risk-of-breast-cancer,2025-06-21 22:19:34.186201,10,38
which medications in the drug class aromatase inhibitors are used in the treatment of breast cancer?,"in patients receiving adjuvant aromatase inhibitor therapy for breast cancer who are at high risk for fracture, the monoclonal antibody denosumab or either of the bisphosphonates zoledronic acid and pamidronate may be added to the treatment regimen to increase bone mass. these agents are given along with calcium and vitamin d supplementation. see link for full list of medications.",Aromatese inhibitors,https://www.medscape.com/answers/1947145-155963/which-medications-in-the-drug-class-aromatase-inhibitors-are-used-in-the-treatment-of-breast-cancer,2025-06-21 22:19:34.186201,16,59
role of tamoxifen in the treatment of DCIS breast cancer,tamoxifen is the only hormonal therapy currently approved for adjuvant therapy in patients treated with breast-conserving surgery and radiation for ductal carcinoma in situ. a retrospective study found that patients with estrogen receptor negativepositive ductal carcinoma in situ who were treated with tamoxifen showed significant decreases in subsequent breast cancer at 10 years. adjuvant tamoxifen also reduces the risk of contralateral breast cancer.,tamoxifen role DCIS treatment,https://www.medscape.com/answers/1947145-155357/what-is-the-role-of-tamoxifen-in-the-treatment-of-dcis-breast-cancer,2025-06-21 22:19:34.186201,10,63
In what ways is breast cancer treated,"surgery and radiation therapy, along with adjuvant hormone or chemotherapy when indicated, are considered primary treatment. surgical therapy may consist of lumpectomy or total mastectomy. radiation therapy may follow surgery in an effort to eradicate residual disease while reducing recurrence rates. there are 2 general approaches for delivering radiation therapy: external-beam radiotherapy (ebrt), partial-breast irradiation (pbi).",treatment ,https://www.medscape.com/answers/1947145-155245/how-is-breast-cancer-treated,2025-06-21 22:19:34.186201,7,56
What role do reproductive variables have in the development of breast cancer,"reproductive factors and steroid hormones late age at first pregnancy, nulliparity, early onset of menses, and late age of menopause have all been consistently associated with an increased risk of breast cancer. prolonged exposure to elevated levels of sex hormones has long been postulated as a risk factor for developing breast cancer, explaining the association between breast cancer and reproductive behaviors.",reproductive ,https://www.medscape.com/answers/1947145-155258/what-is-the-role-of-reproductive-factors-in-the-etiology-of-breast-cancer,2025-06-21 22:19:34.186201,12,61
What role do oral contraceptives (OCs) have in the development of breast cancer,"one of the most widely studied factors in breast cancer etiology is the use of exogenous hormones in the form of oral contraceptives (ocs) and hormone replacement therapy (hrt). the overall evidence suggests an approximately 25 greater risk of breast cancer among current users of ocs. the risk appears to decrease with age and time since oc discontinuance. for oc users, risk returns to that of the average population risk about 10 years after cessation.",oral contraceptives OCs,https://www.medscape.com/answers/1947145-155260/what-is-the-role-of-oral-contraceptives-ocs-in-the-etiology-of-breast-cancer,2025-06-21 22:19:34.186201,13,75
what is breast cancer?,breast cancer is a malignant tumor that develops from the cells of the breast. it is the most common type of cancer among women in the world. it is most often curable when found early. about 80 of breast cancers start in the ducts.,breast cancer,https://www.medscape.com/answers/1947145-155238/what-is-breast-cancer,2025-06-21 22:19:34.186201,4,44
What is considered in the assessment of breast cancer,evaluation of breast cancer includes the following: clinical examination imaging needle biopsy,evaluation,https://www.medscape.com/answers/1947145-155240/what-is-included-in-the-evaluation-of-breast-cancer,2025-06-21 22:19:34.186201,9,12
what are the prognostic stages for breast cancer?,histologic grade (g) gx grade cannot be assessed g1 low combined histologic grade (favorable) g2 intermediate combined histologic grade (moderately favorable) g3 high combined histologic grade (unfavorable),prognostic stages,https://www.medscape.com/answers/1947145-155333/what-are-the-prognostic-stages-for-breast-cancer,2025-06-21 22:19:34.186201,8,27
How is breast cancer screening carried out,early detection remains the primary defense in preventing breast cancer. screening modalities include the following: breast self-examination clinical breast examination mammography ultrasonography magnetic resonance imaging,screening,https://www.medscape.com/answers/1947145-155243/how-is-breast-cancer-screening-performed,2025-06-21 22:19:34.186201,7,25
what are the asco guidelines for adjuvant endocrine therapy in the treatment of postmenopausal women with breast cancer?,"women with stage ii or stage iii breast cancers who would ordinarily be advised to receive adjuvant chemotherapy should receive ovarian suppression in addition to endocrine therapy women with stage i or ii breast cancers at higher risk of recurrence, who might consider chemotherapy, may also be offered ovarian suppression in addition to endocrine therapy women with stage i breast cancers not warranting chemotherapy should receive endocrine therapy but not receive ovarian suppression women with node-negative cancers 1 cm or less (t1a, t1b) should receive endocrine therapy but not receive ovarian suppression ovarian suppression may be administered with either tamoxifen or an aromatase inhibitor",adjuvant endocrine therapy,https://www.medscape.com/answers/1947145-155411/what-are-the-asco-guidelines-for-adjuvant-endocrine-therapy-in-the-treatment-of-postmenopausal-women-with-breast-cancer,2025-06-21 22:19:34.186201,18,104
Inflammatory breast cancer,"ibc is a clinical diagnosis that implies presentation with the cardinal signs of inflammation (calor warmth , rubor redness , tumor mass ) involving the breast, although the warmth may be subtle and the mass may not be appreciated as something discrete. indeed, even when a localized mass is apparent in ibc, the true extent of the disease (as shown by performing skin biopsies from the surrounding normal-appearing skin) is usually greater than is apparent on physical examination.",IBC,https://www.medscape.com/answers/1947145-155361/what-is-inflammatory-breast-cancer-ibc,2025-06-21 22:19:34.186201,3,78
what are the histologic findings of medullary carcinoma breast cancer?,"lobular carcinoma in situ (lobular carcinoma in situ) arises from the terminal duct apparatus and shows a rather diffuse distribution throughout the breast, which explains its presentation as a nonpalpable mass in most cases. over the past 25 years, the incidence of lobular carcinoma in situ has doubled, currently standing at 2. 8 per 100,000 women. the peak incidence is in women aged 40-50 years.",medullary carcinoma,https://www.medscape.com/answers/1947145-155323/what-are-the-histologic-findings-of-medullary-carcinoma-breast-cancer,2025-06-21 22:19:34.186201,10,65
which medications in the drug class pd-1 pd-l1 inhibitors are used in the treatment of breast cancer?,"pd-l1 is expressed on the surface of activated t cells under normal conditions; binding pdl1 inhibits immune activation and reduces t-cell cytotoxic activity when bound. this negative feedback loop is essential for maintaining normal immune responses and limits t-cell activity to protect normal cells during chronic inflammation. tumor cells may circumvent t-cell mediated cytotoxicity by expressing pdl1 on the tumor itself or on tumor-infiltrating immune cells, resulting in the inhibition of immune-mediated killing of tumor cells. see link for full list of medications.",PD-1/PD-L1 PD-1 PD-L1,https://www.medscape.com/answers/1947145-185453/which-medications-in-the-drug-class-pd-1pd-l1-inhibitors-are-used-in-the-treatment-of-breast-cancer,2025-06-21 22:19:34.186201,17,83
Shall I use exemestane,"exemestane is not fda approved for breast cancer risk reduction. however, asco guidelines recommend that it should be discussed as an alternative to tamoxifen and or raloxifene to reduce the risk of invasive bc, specifically estrogen receptor negativepositive bc, in postmenopausal women age 35 years with a 5-year projected absolute bc risk 1. 66 or with lobular carcinoma in situ or atypical hyperplasia. it should not be used for bc risk reduction in premenopausal women. exemestane is given in a dosage of 25 mg per day orally for 5 years.",exemestane,https://www.medscape.com/answers/1947145-155397/what-are-the-asco-recommendations-for-use-of-exemestane-in-breast-cancer-risk-reduction,2025-06-21 22:19:34.186201,4,90
guidelines for sentinel lymph node biopsy,"a 2016 update on slnb for patients with operable early-stage breast cancer by asco advises that slnb may be offered to the following patients: women with multicentric tumors women with ductal carcinoma in situ who will be undergoing mastectomy women who previously underwent breast and or axillary surgery women who received preoperative neoadjuvant systemic therapy according to the asco guidelines, slnb should not be performed in patients with any of the following: large or locally advanced invasive breast cancer (tumor size t3 t4) inflammatory breast cancer ductal carcinoma in situ (when breast-conserving surgery is planned) pregnancy",sentinel lymph node biopsy. axillary lymph node dissection.,https://www.medscape.com/answers/1947145-155400/what-are-the-asco-guidelines-for-the-use-of-sentinel-lymph-node-biopsy-slnb-in-the-treatment-of-breast-cancer,2025-06-21 22:19:34.186201,6,96
what is lump,"if a palpable lump is found and possesses any of the following features, breast cancer may be present: hardness irregularity focal nodularity fixation to skin or muscle",lump palpable,https://www.medscape.com/answers/1947145-155242/what-features-of-a-palpable-lump-suggest-breast-cancer,2025-06-21 22:19:34.186201,3,27
breast cancer assessment algorithm,"breast cancer evaluation should be an ordered inquiry that begins with symptoms and a general clinical history. this is followed by a sequence that has become formalized as triple assessment, which includes the following components: clinical examination imaging (usually mammography, ultrasonography, or both) needle biopsy",triple assessment algorithm,https://www.medscape.com/answers/1947145-155296/what-is-the-triple-assessment-algorithm-for-breast-cancer-diagnosis,2025-06-21 22:19:34.186201,4,45
role of mastecomy in the prevention of breast cancer,"in retrospective studies with median follow-up periods of 13-14 years, bilateral risk-reduction mastectomy decreased the risk of developing breast cancer by at least 90 in women at moderate to high risk and in those with known brca1 2 mutations. in women with deleterious mutations in other genes that are associated with a 2-fold or greater risk for breast cancer but without a compelling family history of breast cancer, the value of risk-reducing mastectomy is unknown. note: woman who are considering prophylactic mastectomy should meet with a range of specialists to discuss the risks and benefits of surgery, including its potential psychosocial effects, as well as the nonsurgical options for reducing risk of breast cancer. these may include a breast health specialist, medical social worker, or cancer clinical psychologist or psychiatrist.",mastecomy,https://www.medscape.com/answers/1947145-155374/what-is-the-role-of-mastectomy-in-the-prevention-of-breast-cancer,2025-06-21 22:19:34.186201,9,130
Which physical signs are indicative of breast cancer,the following physical findings should raise concern: lump or contour change skin tethering nipple inversion dilated veins ulceration paget disease edema or peau d orange,indicative indicators,https://www.medscape.com/answers/1947145-155241/which-physical-findings-suggest-breast-cancer,2025-06-21 22:19:34.186201,8,25
When to use Tyrosine Kinase Inhibitors,tyrosine kinase inhibitors play an important role in the modulation of growth factor signaling. they are commonly combined with other forms of chemotherapy or radiation therapy. see link for full list of medications.,Tyrosine Kinase Inhibitors,https://www.medscape.com/answers/1947145-155965/which-medications-in-the-drug-class-tyrosine-kinase-inhibitors-are-used-in-the-treatment-of-breast-cancer,2025-06-21 22:19:34.186201,6,33
What is the role of breast cancer medicine treatment,"in patients receiving adjuvant aromatase inhibitor therapy for breast cancer who are at high risk for fracture, the monoclonal antibody denosumab or either of the bisphosphonates zoledronic acid and pamidronate may be added to the treatment regimen to increase bone mass. these agents are given along with calcium and vitamin d supplementation.",medicine medication,https://www.medscape.com/answers/1947145-155247/what-is-the-role-of-drug-treatment-for-breast-cancer,2025-06-21 22:19:34.186201,9,52
do adjuvent therapies work,"adjuvant treatment for breast cancer involves radiation therapy and a variety of chemotherapeutic and biologic agents. it is designed to treat micrometastatic disease (or breast cancer cells that have escaped the breast and regional lymph nodes but which have not yet had an established identifiable metastasis). treatment is aimed at reducing the risk of future recurrence, thereby reducing breast cancer related morbidity and mortality. in patients receiving adjuvant aromatase inhibitor therapy for breast cancer who are at high risk for fracture, the monoclonal antibody denosumab or either of the bisphosphonates zoledronic acid and pamidronate may be added to the treatment regimen to increase bone mass. these agents are given along with calcium and vitamin d supplementation.",adjuvent therapy,https://www.medscape.com/answers/1947145-155415/what-is-the-role-of-adjuvant-therapies-in-the-treatment-of-breast-cancer,2025-06-21 22:19:34.186201,4,116
Why is anatomy important in relation to breast cancer,"the breasts of an adult woman are milk-producing glands on the front of the chest wall. they rest on the pectoralis major and are supported by and attached to the front of the chest wall on either side of the sternum by ligaments. each breast contains 15-20 lobes arranged in a circular fashion. for more information, visit:",anatomy ,https://www.medscape.com/answers/1947145-155249/what-is-the-anatomy-relevant-to-breast-cancer,2025-06-21 22:19:34.186201,9,57
which history findings increase the risk for a second primary breast cancer occurrence?,a history of breast cancer is associated with a 3- to 4-fold increased risk of a second primary cancer in the contralateral breast. the presence of any premalignant ductal carcinoma in situ (ductal carcinoma in situ) or lobular carcinoma in situ confers an 8- to 10-fold increase in the risk of developing breast cancer in women who harbor untreated preinvasive lesions.,historical factors,https://www.medscape.com/answers/1947145-155264/which-history-findings-increase-the-risk-for-a-second-primary-breast-cancer-occurrence,2025-06-21 22:19:34.186201,13,61
efficacy of combination therapy in the treatment of triple-negative breast cancer,"unresectable metastatic triple-negative breast cancer (ie, estrogen receptor negative, progesterone receptor negative, and her2 receptor negative) is aggressive and carries a poor prognosis. however, combination therapy with the programmed cell death ligand 1 (pdl1) inhibitor atezolizumab plus nanoparticle albumin-bound (nab) paclitaxel has been shown to prolong pfs in these patients. in 2019, fda approved atezolizumab in combination with nab-paclitaxel for triple-negative breast cancer. the combination therapy attacked the tumor on two fronts. on one side, the chemotherapy drug cyclophosphamide eliminated tumor cells, while on the other front, another drug inhibited tumor-associated cells called macrophages, which block the body s immune response against the tumor. this two-front strategy effectively treated several highly aggressive tnbc primary tumors and metastasis",triple-negative breast cancer treatment ,"https://www.medscape.com/answers/1947145-155369/what-is-the-efficacy-of-combination-therapy-in-the-treatment-of-triple-negative-breast-cancer

https://www.bcm.edu/news/a-promising-combination-therapy-for-triple-negative-breast-cancer",2025-06-21 22:19:34.186201,11,117
what is the role of mri in the workup of breast cancer?,"in an effort to overcome the limitations of mammography and ultrasonography, mri has been explored as a modality for detecting breast cancer in women at high risk and in younger women. a combination of t1, t2, and 3-d contrast-enhanced mri techniques has been found to possess high sensitivity (approximating 86-100 in combination with mammography and clinical breast examination) to malignant changes in the breast.",MRI role,https://www.medscape.com/answers/1947145-155309/what-is-the-role-of-mri-in-the-workup-of-breast-cancer,2025-06-21 22:19:34.186201,12,64
How is radiation-induced heart disease in breast cancer patients monitored,"according to a consensus statement from the european association of cardiovascular imaging and the american society of echocardiography, patients treated with radiotherapy to the chest for hodgkin's disease, or breast, lung, or esophageal cancer, should have an echocardiogram every 5 to 10 years to detect radiation-induced heart disease (rihd). the relative risk of rihd is 2- to 5. 9 times higher in patients treated with radiation for breast cancer.",heart disease,https://www.medscape.com/answers/1947145-155380/how-is-radiation-induced-heart-disease-monitored-in-patients-with-breast-cancer,2025-06-21 22:19:34.186201,10,69
Breast cancer screening categories,"the acog released guidelines for breast cancer risk assessment and screening in average-risk women in 2017. 184 for women at average risk, acog categorizes its recommendations as follows: level a based on good and consistent scientific evidence level b based on limited or inconsistent scientific evidence level c based primarily on consensus and expert opinion acog recommends that health care providers periodically assess patients' breast cancer risk by reviewing the history (level b). breast cancer risk factors include a long list. visit the provided link for more information.",breast cancer screening guidelines,https://www.medscape.com/answers/1947145-155389/how-are-the-acog-guidelines-for-breast-cancer-screening-categorized,2025-06-21 22:19:34.186201,4,88
what is the efficacy of external-beam radiotherapy (ebrt) in the treatment of breast cancer?,"the most common type of radiation therapy for breast cancer, ebrt is generally given after other treatments are complete. in ebrt, a beam of radiation, a high-energy x-ray, is focused on the spot where the cancer was removed. if a lumpectomy was performed, a patient may receive ebrt to the entire breast, a technique called whole-breast radiation. ebrt may also be delivered to nearby lymph nodes. some advantages of ebrt for breast cancer patients may include: 1) it is fast, painless and performed as an outpatient procedure. 2) unlike chemotherapy, which circulates throughout the body, ebrt is targeted to the treatment area. 3) at no point during radiation therapy is a patient radioactive, and there s no risk of radioactivity to your friends and family.",external-beam radiotherapy efficacy (EBRT),https://www.cancercenter.com/cancer-types/breast-cancer/treatments/radiation-therapy,2025-06-21 22:19:34.186201,14,125
breast biospy role in breast cancer diagnosis,"percutaneous vacuum-assisted large-gauge core-needle biopsy (vacnb) with image guidance is the recommended diagnostic approach for newly diagnosed breast tumors. core biopsies can minimize the need for operative intervention (and subsequent scarring, and provide accurate pathologic diagnosis for appropriate management. excisional biopsy, as the initial operative approach, has been shown to increase the rate of positive margins. open excisional biopsy is reserved for lesions where the diagnosis remains equivocal despite imaging and core biopsy assessment or for benign lesions that the patient chooses to have removed. because wide clearance of the lesion is usually not the goal in diagnostic biopsies, unnecessary distortion of the breast is thereby avoided. ongoing audit is essential to help reduce an excessive benign-to-malignant biopsy ratio.",breast biospy role,https://www.medscape.com/answers/1947145-155316/what-is-the-role-of-breast-biopsy-in-the-diagnosis-of-breast-cancer,2025-06-21 22:19:34.186201,7,119
what are the asbrs selection criteria for treatment of breast cancer with accelerated partial breast irradiation (pbi)?,"the american society of breast surgeons (asbrs) recommends the following selection criteria when patients are being considered for treatment with accelerated pbi : 1) age 45 years for all tumor types 2) all invasive subtypes or ductal carcinoma in situ 3) total tumor size (invasive and ductal carcinoma in situ) 3 cm 4) t stage tis, t1, t2 ( 3 cm) 5) margins; no tumor on ink for invasive tumors or tumors involved with ductal carcinoma in situ; 2 mm for ductal carcinoma in situ 6) node negative 7) multifocal acceptable if total span of tumors is 3 cm 8) estrogen receptor positive or negative 9) focal lymphovascular invasion 10) no genetic mutations",ASBrS selection criteria,https://www.medscape.com/answers/1947145-155348/what-are-the-asbrs-selection-criteria-for-treatment-of-breast-cancer-with-accelerated-partial-breast-irradiation-pbi,2025-06-21 22:19:34.186201,17,113
how is ductal carcinoma in situ breast cancer treated?,"currently, the standard treatment of ductal carcinoma in situ is surgical resection with or without radiation. adjuvant radiation and hormonal therapies are often reserved for younger women, patients undergoing lumpectomy, or those with the comedo subtype. local treatment for ductal carcinoma in situ usually involves breast-conserving therapy (bct), which consists of lumpectomy (also called wide excision or partial mastectomy) followed in most cases by adjuvant radiation therapy (rt). alternatively, mastectomy may be considered",DCIS treatment,"
https://www.medscape.com/answers/1947145-155355/how-is-dcis-breast-cancer-treated

https://www.uptodate.com/contents/ductal-carcinoma-in-situ-treatment-and-prognosis#:~:text=Local%20treatment%20for%20DCIS%20usually,Alternatively%2C%20mastectomy%20may%20be%20considered.
",2025-06-21 22:19:34.186201,9,73
3D mammography efficacy,"in the screening with tomosynthesis or standard mammography-2 (storm-2) study a prospective population-based screening study in 9672 women that compared integrated 3d mammography with 2d mammography 3d mammography detected more cases of breast cancer than 2d mammography but increased the percentage of false-positive recalls in sequential screen-reading. thus, the benefit of significantly increased breast cancer detection with tomosynthesis screening must be weighed against the possible risk of overdiagnosis.",3D mammography efficacy,https://www.medscape.com/answers/1947145-155305/what-is-the-efficacy-of-3d-mammography-for-breast-cancer-screening,2025-06-21 22:19:34.186201,3,68
How likely is metaplastic breast cancer to progress,"for metaplastic breast cancer, the majority of published case series have demonstrated a worse prognosis than with infiltrating ductal carcinoma, even when adjusted for stage, with a 3-year overall survival rate of 48-71 and 3-year disease-free survival rate of 15-60. in most case series, large tumor size and advanced stage have emerged as predictors of poor overall survival and prognosis. nodal status does not appear to impact survival in metaplastic breast cancer.",metaplastic,https://www.medscape.com/answers/1947145-155286/what-is-the-prognosis-of-metaplastic-breast-cancer,2025-06-21 22:19:34.186201,8,72
ASCO guidelines for monitoring bone density following the treatment for breast cancer,"women aged 65 years ----------------------------------------------------------------------- woman aged 60-64 years with 1 of the following: 1. family history of osteoporosis 2. low body weight 3. prior nontraumatic fracture 4. other risk factors (eg, smoking, sedentary lifestyle) ----------------------------------------------------------------------- postmenopausal women on aromatase inhibitors ----------------------------------------------------------------------- premenopausal women who develop treatment related premature menopause -----------------------------------------------------------------------",monitoring bone density ASCO guidelines,https://www.medscape.com/answers/1947145-155377/what-are-asco-guidelines-for-monitoring-bone-density-following-the-treatment-for-breast-cancer,2025-06-21 22:19:34.186201,12,51
